News
Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirror that of Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1 like Foundayo and a triple-G therapy like retatrutide.
FEATURED STORIES
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
THE LATEST
Pfizer and BioNTech requested the FDA authorize booster shots for their COVID-19 vaccine for all adults 18 years and older, presenting data not available in September.
The drug for treatment-resistant depression reportedly demonstrated significant improvement in patients at its highest dose of 25 mg. Here’s more about it.
Angany entered into collaboration for a series of preclinical studies that will evaluate the safety and efficacy of BP/AH-01, Angany’s lead peanut allergy biological candidate.
Public Citizen urged NIH director Dr. Francis Collins to clarify the NIH’s role in Moderna’s vaccine publicly and explain what he plans to ensure that federal scientists are credited for their work.
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here’s who snagged funding this week.
DeepCure announced the closing of its $40 million Series A financing round. The round, led by Morningside Ventures, brings the company’s total amount raised to $47 million since it was founded in 2018.
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
AstraZeneca announced its plans to create a new, separate division for vaccines and antibody therapies, specifically its COVID-19 vaccine developed with the University of Oxford and other COVID-19 antibody treatments.
Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.
Although Martin Shkreli continues to serve a prison sentence for fraud, the so-called “Pharma Bro” remains in legal hot water over antitrust charges.